louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01761682: Acute Lymphoblastic Leukemia Registry at Asan Medical Center
Official title: Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Leukemia, Acute Lymphoblastic
Precursor B-Cell Lymphoblastic Leukemia
Leukemia, Biphenotypic, Acute
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Lymphoblastic Lymphoma
Lead sponsor: Asan Medical Center
Sponsor class: OTHER
First posted: 2013-01-07
Enrollment: 200
Sex: ALL
Minimum age (years): 15
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who are diagnosed and/or treated with acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea

Brief summary: The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

Detailed description: 1. Acquisition of informed concent form
2. Data acquisition from medical record including

   * demographic / disease-associated factors
   * details of treatment, and its results
   * complications during treatment
   * genetic data
   * survival outcome (upto 10 years)
3. Accumulation of data for 30 years
4. Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)

Eligibility criteria: Inclusion Criteria:

* All patients who are diagnosed and/or treated as acute lymphoblastic leukemia at Asan Medical Center (including biphenotypic acute leukemia with Philadelphila-positive, Burkitt leukemia/lymphoma)
* 15 years of age and over
* All patients who give written consent according to guidelines at Asan Medical Center committee on human research

Exclusion Criteria:

* Patients who refuse to give consent to registering

Primary outcomes:
measure: Overall survival
timeFrame: 10 year
Secondary outcomes:
measure: Event-free survival
timeFrame: 10 years
measure: Relapse-free survival
timeFrame: 10 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
Study officials:
affiliation: Associate Professor
name: Dae-Young Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00189982: Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101
Official title: Recombinant Antihemophilic Factor Manufactured and Formulated Without Added Human or Animal Proteins (ADVATE rAHF-PFM): Safety Monitoring in Pediatric Patients Diagnosed With Severe to Moderately Severe Hemophilia A - A Continuation of Baxter Clinical Study 060101
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Hemophilia A
Keywords: Factor VIII Deficiency
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2005-09-19
Enrollment: 4
Sex: MALE
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate whether rAHF-PFM is safe and effective in the treatment of children with hemophilia A. The study is open to pediatric patients in Canada who completed Baxter Study 060101.


Eligibility criteria: Inclusion Criteria:

* Subject must have participated and completed participation in Baxter's clinical study 060101
* Subject or parent/legally authorized representative has provided written informed consent

Exclusion Criteria:

* Subjects who have withdrawn from Baxter's Clinical Study 060101 prior to the termination of the study

Primary outcomes:
measure: Assessment of safety, as measured by the incidence, causality, and severity of adverse experiences
timeFrame: Throughout the study period of approximately 23 months.
Secondary outcomes:
measure: Assessment of the hemostatic efficacy in the treatment of bleeding episodes;
timeFrame: At least 50 exposure days or a total treatment time of 6 months, whichever came first.
measure: assessment of the hemostatic efficacy in surgical or invasive procedures
timeFrame: From day of surgery until time of discharge from hospital or clinic (up to approximately 2 weeks post surgery).
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: Hospital for Sick Children
state: Ontario
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT05049382: Does Extraction Difficulty of Mandibular Impacted Third Molars Mirror Post-op Outcomes?
Official title: Does Extraction Difficulty of Mandibular Impacted Third Molars Mirror Post-op Outcomes?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Impacted Third Molar Tooth
Lead sponsor: Selcuk University
Sponsor class: OTHER
First posted: 2021-09-20
Enrollment: 66
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The tooth of the patient who applies to the clinic for the impacted wisdom tooth will be classified according to Escoda's difficulty classification. Before the extraction, patients' interincisal, tragus-commissural, and lateral canthus-angulus distances, Oral Health Impact Profile -14 (OHIP-14) scores, and serum levels of CRP and D-Dimer will be measured.

Operation time will be recorded. After the operation, on 4th-day patients' patients' interincisal, tragus-commissural, and lateral canthus-angulus distances, Oral Health Impact Profile -14 (OHIP-14) scores, and serum levels of CRP and D-Dimer and Visual Analogue Scale (for pain) scores will be measured and recorded. On the 10th day, all these measurements will be repeated.

All recorded data will be evaluated for possible correlations based on extraction difficulties.


Eligibility criteria: Inclusion Criteria:

* Having extraction of only the mandibular third molar
* No systemic disease
* Signing an informed consent
* No dental phobia or anxiety
* No lesion around the impacted tooth
* Presence of adjacent second molar

Exclusion Criteria:

* Infection after surgery
* Alveolar osteitis
* Not to participate in any follow-up control appointments

Primary outcomes:
measure: interincisal distance change
timeFrame: before the surgery, 4th and 10th days
measure: tragus-commissura distance
timeFrame: before the surgery, 4th and 10th days
measure: lateral canthus-angulus distance
timeFrame: before the surgery, 4th and 10th days
measure: OHIP-14 score
timeFrame: before the surgery, 4th and 10th days
measure: VAS score
timeFrame: 4th and 10th days
measure: Operation time
timeFrame: after the operation
measure: CRP serum level
timeFrame: before the surgery and 4th day
measure: D-Dimer serum level
timeFrame: before the surgery and 4th day
Secondary outcomes:
Other outcomes:
Locations:
city: Selçuklu
country: Turkey
facility: Selcuk University, Dentistry Faculty
state: Konya
Study officials:
affiliation: Selcuk Universty/Dentistry Faculty
name: Gökhan Gürses
role: STUDY_CHAIR
affiliation: Selcuk Universty/Dentistry Faculty
name: Mert Doğrul
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03133182: Polypharmacy and Outcomes After Elective Noncardiac Surgery
Official title: Association of Polypharmacy With Outcomes After Elective Noncardiac Surgery: a Population-based Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Polypharmacy
Surgical Procedure, Operative
Morality
Epidemiology
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
First posted: 2017-04-28
Enrollment: 266499
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Population-based sample of people having their first eligible surgery during the study period

Brief summary: This study investigates the association of preoperative polypharmacy with outcomes and healthcare resource utilization in a population-based sample of older patients enrolled in a universal pharmacare program

Detailed description: Multilevel multivariable regression analysis will be used to investigate the adjusted association between preoperative polypharmacy and postoperative outcomes and healthcare resource utilization. Sensitivity analyses will be used to evaluate the robustness of the primary analysis.

Eligibility criteria: Inclusion Criteria:

* Intermediate to high risk elective non-cardiac surgery
* Age \>=66 on day of surgery

Exclusion Criteria:

-

Primary outcomes:
measure: Mortality
timeFrame: from day of surgery up to 90 days after surgery
Secondary outcomes:
measure: Complications
timeFrame: From day of surgery to day of hospital discharge, up to 365 days after surgery
measure: Length of Stay
timeFrame: date of surgery to date of hospital discharge, or 365 days after surgery, whichever comes first
measure: Costs of Care
timeFrame: date of surgery up to 90 days after surgery
measure: Institutional Discharge
timeFrame: date of surgery to date of hospital discharge, or 365 days after surgery, whichever comes first
measure: Hospital Readmission
timeFrame: From the date of hospital discharge to 30 days after the date of discharge
Other outcomes:
Locations:
Study officials:
References:
citation: McIsaac DI, Wong CA, Bryson GL, van Walraven C. Association of Polypharmacy with Survival, Complications, and Healthcare Resource Use after Elective Noncardiac Surgery: A Population-based Cohort Study. Anesthesiology. 2018 Jun;128(6):1140-1150. doi: 10.1097/ALN.0000000000002124.
Clinical trial NCT00990782: Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment
Official title: CEPELA I Trial: Capsule Endoscopy for Post-Ablation Esophageal Lesion Assessment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Esophageal Lesion
Lead sponsor: The Cleveland Clinic
Sponsor class: OTHER
Collaborators: name: Medtronic - MITG
First posted: 2009-10-07
Enrollment: 93
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study utilizes a disposable capsule endoscope (Pillcam ESO) to assess the condition of a patient's esophagus before and after the RFA procedure, as the injury rate to the esophagus has not been established.

Detailed description: Patients undergoing radiofrequency ablation (RFA) therapy for atrial fibrillation, can sometimes experience insult or injury to the esophagus, due to the proximity of the esophagus to the RFA treatment area. This study utilizes a disposable capsule endoscope (Pillcam ESO) to assess the condition of a patient's esophagus before and after the RFA procedure, as the injury rate to the esophagus has not been established.

Eligibility criteria: Inclusion Criteria:

* Symptomatic patients with persistent atrial fibrillation selected for radiofrequency ablation
* Adults aged 18 years and older
* Patients able to give informed consent

Exclusion Criteria:

* Patients under the age of 18
* Patient unable to or unwilling to swallow the capsule endoscopes
* Patients with cardiac pacemakers, implanted cardiac defibrillators or other implanted electro-medical devices
* Pregnant or lactating females
* Subjects with history of abdominal, pelvic, or bowel surgery within the past year

Primary outcomes:
measure: Number of Participants With Esophageal Lesions Identified Using Capsule Endoscopy
timeFrame: 14 days
Secondary outcomes:
measure: Number of Participants With Capsule-identified Esophageal Injury Who Report Symptoms Post-RFA
timeFrame: 14 Days
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Milan Dodig, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05542082: Pilot Study of the CHILLS Cryotherapy System for the Treatment of OSA
Official title: OUS Multicenter Pilot Study of the CHILLS Cryotherapy System for the Treatment of Obstructive Sleep Apnea (ARCTIC-2)
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Obstructive Sleep Apnea of Adult
Lead sponsor: Cryosa, Inc.
Sponsor class: INDUSTRY
First posted: 2022-09-15
Enrollment: 50
Sex: ALL
Minimum age (years): 22
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a prospective, multicenter, non-randomized single-arm safety and efficacy study to:

* Collect data to evaluate the safety of CHILLS cryotherapy to treat OSA in patients with moderate to severe disease.
* Evaluate the chronic performance of the CHILLS system and collect clinical measures for therapy effectiveness that will be used to demonstrate safety and effectiveness in the next clinical study.

Detailed description: The study will enroll up to 3 sites in Latin America, enrollment is competitive.

Up to 70 subjects will receive treatment and be followed through their 3-month visit.

Long-term follow-up will continue every 6 months out to 2 years post-procedure, with an option to follow patients up to 5 years.

Eligibility criteria: Inclusion Criteria:

Likely suffer moderate to severe OSA based on history and physical or have an established diagnosis of moderate to severe OSA (AHI ≥ 10) based on a prior sleep study.

A confirmation baseline sleep study will be performed after enrollment to verify AHI ≥ 10 and ≤ 50, and mixed and central apneas total ≤ 25% of apneas for continued eligibility.

Have either failed Positive Airway Pressure (PAP) therapy or decline PAP therapy

BMI of 25 - 40 kg/m2 at enrollment

Negative result for COVID-19 polymerase chain reaction (RT-PCR) test and absence of clinical symptoms for long COVID-19 relating to deterioration of taste, smell.

Exclusion Criteria:

Unable or incapable of providing informed written consent

Unwilling or incapable of returning to all follow-up visits and sleep studies, including evaluation procedures and filling out questionnaires

Primary outcomes:
measure: Incidence of Serious Procedure-Related Complications
timeFrame: 90 Days
Secondary outcomes:
Other outcomes:
measure: Sleep Testing
timeFrame: 90 days, 6-, 12- and 24-months
measure: Epworth Sleepiness Survey (ESS)
timeFrame: 90 days, 6-, 12-, 18- and 24-months
measure: Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10)
timeFrame: 90 days, 6-, 12-, 18- and 24-months
measure: Pain Visual Analog Scale (VAS)
timeFrame: Discharge (day 1), 7 days, 30 days, 90 days and every 6 months through 2 years
measure: Eating Assessment Tool (EAT-10)
timeFrame: 7 days, 30 days, 90 days and every 6 months through 2 years
Locations:
city: Panama City
country: Panama
facility: Paitilla Medical Center
city: Panama City
country: Panama
facility: Punta Pacifica Hospital
Study officials:
affiliation: San Fernando Specialized Center
name: Stella Rowley, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05625282: Plantar Plate Repair for Treatment of Floating Toe: Must we Associate it to Weil Osteotomy?
Official title: Plantar Plate Repair for Treatment of Floating Toe: Must we Associate it to Weil Osteotomy?
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Floating Toe
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
First posted: 2022-11-22
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to assess if isolated Weil osteotomy for floating toe grade II or III provides results that are not inferior to those obtained with the Weil osteotomy associated with plantar plate repair.


Eligibility criteria: Inclusion Criteria:

* 18 years old, minimum
* ability to understand treatment and recovery
* floating toe

Exclusion Criteria:

* age less than 18 years old at the moment of recruiting
* patients who are not able to understand treatment and recovery
* intraoperative diagnosis of plantar plate injury grade 0, I or IV in Nery's classification
* secondary surgery

Primary outcomes:
measure: Manchester-Oxford Foot Questionnaire (MOXFQ) score at the end of follow-up
timeFrame: 1 year
Secondary outcomes:
measure: age
timeFrame: moment of recruiting
measure: sex
timeFrame: moment of recruiting
measure: side
timeFrame: moment of recruiting
measure: rate of recurrence
timeFrame: 1 month, 3 months, 6 months, 1 year after surgery
measure: rate of complications
timeFrame: 1 month, 3 months, 6 months, 1 year after surgery
measure: Score obtained at Manchester-Oxford Foot and Ankle Questionnaire (0-100, where higher scores mean a worse outcome)
timeFrame: 3 months, 6 months after surgery
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
Study officials:
References:
Clinical trial NCT06875882: Evaluating Occupational Stress in Surgeons and Musicians: A Multi-modal Pilot Study Using Wearable EEG, Biomarker Analysis and Validated Questionnaires
Official title: Evaluating Occupational Stress in Surgeons and Musicians: A Multi-modal Pilot Study Using Wearable EEG, Biomarker Analysis and Validated Questionnaires
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Occupational Stress
Lead sponsor: M.D. Anderson Cancer Center
Sponsor class: OTHER
First posted: 2025-03-13
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: MD Anderson Cancer Center

Brief summary: To learn about occupational stress among surgeons and musicians by integrating psychological assessments, neurophysiological measures, and biomarkers.

Detailed description: Primary Objectives • To assess the change in occupational stress among surgeons and musicians by measuring physiological and psychological stress markers.

Endpoints:

* Changes in salivary cortisol levels (before and after surgeries for surgeons and live public performances for musicians).
* Changes in State-Trait Anxiety Inventory-Short (STAI-S) scores (administered pre- and post-surgery/performance).

SECONDARY OBJECTIVES AND ENDPOINTS

• Assessing and comparing anxiety and burnout, based on the MBI, STAI-T, M-PAS, and SCAT, in surgeons and musicians

Endpoints:

* Baseline levels of anxiety and burnout measured using the MBI, M-PAS, STAI-T, and SCAT.
* Emotional exhaustion, depersonalization, and personal accomplishment from the MBI in both groups.

Eligibility criteria: Inclusion Criteria:

* Adults aged 18 years and older
* Professional musicians (i.e., those with academic or orchestral appointments) or MD Anderson Neurosurgeons
* For Musicians only: You will have a musical performance within three months of study enrollment.

For Neurosurgeons only: You will perform a surgical procedure within three months of study enrollment.

Exclusion Criteria:

* Individuals who are unable to provide informed consent
* Individuals diagnosed with severe cognitive impairments, severe psychiatric disorders, or hearing or visual impairments that could affect participation
* Individuals previously enrolled in the study
* Non-English-speaking musicians and/or surgeons

Primary outcomes:
measure: Safety and Adverse Events (AEs).
timeFrame: Through study completion; an average of 1 year.
Secondary outcomes:
Other outcomes:
Locations:
city: Houston
country: United States
facility: MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: M.D. Anderson Cancer Center
name: Mei Rui, DMA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02812082: Web-based Patient Education Program to Manage Side Effects of Allogeneic Stem Cell Transplant
Official title: Developing and Assessing the Feasibility of Implementing a Video Web-based Patient Education Application
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Allo-SCT Patients
Adult Allo-SCT Survivor
Keywords: Web-based
patient education application
16-769
Lead sponsor: Memorial Sloan Kettering Cancer Center
Sponsor class: OTHER
First posted: 2016-06-23
Enrollment: 0
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to develop an interactive web-based patient education program to help educate patients about the increased risk of MS and its cardiac risk factors following allo-SCT and to inform and motivate patients how to make lifestyle changes. This program will be used in addition to counseling at participants clinic visits. The investigators are not changing the recommendations for prevention and management of these conditions, but rather are trying to improve the way they provide this education to patients.


Eligibility criteria: Inclusion Criteria:

* The option to participate will be offered to male and female allo-SCT patients at MSK ≥ 21 years of age who are greater than 90 days post-transplant and followed in or referred to the adult allo-SCT survivorship clinic at MSK
* The option to participate will be offered to male and female allo-SCT patients at MSK ≥ 21 years of age who are greater than 90 days post-transplant and disease free, but have not yet been referred to the survivorship clinic
* Able to understand written and oral English

Exclusion Criteria:

* Patients less than 90 days post-transplant
* Patients without internet access
* Adult post-transplant patients who have relapsed prior to study recruitment

Primary outcomes:
measure: Percentage of patients that use the application
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: Memorial Sloan Kettering Cancer Center
state: New York
Study officials:
affiliation: Memorial Sloan Kettering Cancer Center
name: Kara Mosesso, NP
role: PRINCIPAL_INVESTIGATOR
References: